# MOTS-c Peptide

> MOTS-c is a mitochondria-derived peptide that activates metabolic stress signaling, AMPK biology, glucose handling, exercise adaptation, and muscle metabolism.

Canonical: https://pepflow.app/peptides/mots-c/

The Mito Signal

A 16-amino-acid mitochondria-derived peptide linked to metabolic stress signaling, AMPK biology, exercise adaptation, insulin sensitivity, and muscle-metabolism research.

Anti-aging  Muscle performance  Metabolic health

Tier D

Evidence Preliminary

Safety Limited Data

FDA status Not Approved

Last reviewed August 11, 2026 47 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is MOTS-c?

MOTS-c is encoded within the mitochondrial 12S rRNA region and is one of the best-known mitochondria-derived peptides. Its discovery helped expand the view of mitochondria from power generators to signaling organelles that can send peptide messages to the nucleus and other tissues.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/31378979/>)

The core research theme is metabolic stress adaptation. MOTS-c has been linked with AMPK activation, nuclear gene-expression changes under stress, glucose handling, muscle metabolism, and exercise-related signaling in preclinical and human-association literature.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29983246/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/33554779/>)

Naming is inconsistent across sources: MOTS-c, MOTs-C, and mitochondrial ORF of the 12S rRNA type-c usually refer to the same 16-amino-acid mitochondrial peptide. The mitochondrial origin matters because the peptide is framed as a signaling message from mitochondrial DNA, not a conventional nuclear-encoded hormone.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/31378979/>) For more context, read the [MOTS-c calculation walkthrough](<https://pepflow.app/blog/mots-c-dosage-calculator/>).

## What MOTS-c is investigated for

MOTS-c evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Insulin sensitivity and metabolic health Injectable 52% Emerging

MOTS-c is a metabolic-homeostasis candidate with a recruiting prediabetes and overweight trial; efficacy cannot be inferred until interventional results are posted.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>)

#### Human evidence

A Phase 2 trial is recruiting adults with prediabetes and overweight or obesity, but no outcome results are posted.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>)

#### Animal / mechanistic evidence

Preclinical work supports metabolic homeostasis and insulin-resistance biology.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>)

### ### Mitochondrial stress adaptation Injectable 44% Preliminary

Mitochondrial stress-adaptation support is meaningful mechanistically, while clinical translation remains early.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29983246/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/31378979/>)

#### Human evidence

Human clinical meaning is not settled, but the pathway is relevant to metabolic-stress research.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29983246/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/31378979/>)

#### Animal / mechanistic evidence

MOTS-c translocates to the nucleus and regulates nuclear gene expression in response to metabolic stress.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29983246/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/31378979/>)

### ### Exercise adaptation and muscle metabolism Injectable 32% Limited

Exercise-mimetic claims should remain mechanism and model based until exogenous MOTS-c performance trials report outcomes.[\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/33554779/>)

#### Human evidence

Controlled human performance outcomes with exogenous MOTS-c have not been established.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/34351816/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

#### Animal / mechanistic evidence

Reviews and preclinical studies link MOTS-c with exercise, mitohormesis, muscle-atrophy signaling, and skeletal-muscle mitochondrial bioenergetics.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/33554779/>) [\[41\]](<https://pubmed.ncbi.nlm.nih.gov/41520850/>)

### ### Cardiovascular risk reduction Injectable 30% Limited

Cardiovascular benefit remains a biomarker and preclinical hypothesis, not an established prevention or treatment claim.[\[27\]](<https://pubmed.ncbi.nlm.nih.gov/39111290/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/36156853/>)

#### Human evidence

Human cardiovascular evidence is limited to observational biomarker and risk-prediction studies rather than MOTS-c treatment trials.[\[27\]](<https://pubmed.ncbi.nlm.nih.gov/39111290/>) [\[30\]](<https://pubmed.ncbi.nlm.nih.gov/40104672/>)

#### Animal / mechanistic evidence

Animal and tissue studies report myocardial-performance, heart-failure, and diabetic-heart signals tied to MOTS-c biology.[\[14\]](<https://pubmed.ncbi.nlm.nih.gov/34635713/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/36156853/>) [\[34\]](<https://pubmed.ncbi.nlm.nih.gov/40661667/>)

### ### Longevity and age-related decline Injectable 24% Limited

Longevity positioning should stay mechanistic; the current evidence does not establish MOTS-c as an anti-aging treatment.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/33473109/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/36233287/>)

#### Human evidence

No controlled human trial shows that exogenous MOTS-c slows aging or improves longevity outcomes.[\[18\]](<https://pubmed.ncbi.nlm.nih.gov/36233287/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/36670507/>)

#### Animal / mechanistic evidence

Mouse and review literature links MOTS-c to age-dependent physical decline, stress-response biology, and age-related disease mechanisms.[\[9\]](<https://pubmed.ncbi.nlm.nih.gov/33473109/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/36233287/>) [\[20\]](<https://pubmed.ncbi.nlm.nih.gov/36670507/>)

## Evidence snapshot

### Overall confidence

Preliminary

45%

MOTS-c has a credible mitochondrial-signaling rationale and active Phase 2a trial context. Practical confidence remains preliminary until controlled human outcome results are available.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>) [\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

38%

### Human evidence

Preliminary

Published human work is mostly association and trial activity rather than posted efficacy outcomes. The Phase 2a metabolic trial is a translation signal, not proof of benefit.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

48%

### Animal / preclinical

Preliminary

Animal and cell studies repeatedly support metabolic homeostasis, insulin resistance, muscle signaling, and stress-response biology. Translation to user-facing outcomes remains the limiting step.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/33554779/>)

66%

### Mechanism support

Moderate

Mitochondrial-to-nuclear signaling and AMPK-linked stress responses give MOTS-c a strong mechanistic frame. Mechanism strength does not replace human outcome data.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29983246/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/31378979/>)

## Forms & administration

MOTS-c is mainly discussed as an injectable research-market protocol. Common practical patterns use morning or pre-workout dosing with an 8-12 week metabolic reassessment window.[\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>) [\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common injectable protocols use 5-10 mg per dose.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

### Frequency

Usually taken once daily.[\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

### Timing Considerations

Common timing is morning or before a workout.[\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

### Cycle Length

Common cycles run 8-12 weeks.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

[Full MOTS-c dosage guide](<https://pepflow.app/peptides/mots-c/dosage/>)

## What to expect

### Weeks 1-2

Injectable metabolic use may show up first as changes in energy, training tolerance, appetite, or sleep, while body-composition and lab shifts remain slower.[\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

### Weeks 4-8

Waist, weight trend, fasting glucose, and training capacity become more meaningful when diet and activity stay consistent.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

### Weeks 8-12

A full cycle may show whether metabolic markers, body-composition trend, or subjective performance moved together rather than as isolated day-to-day noise.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

### After stopping

Energy and training changes may fade toward baseline after the cycle, while metabolic markers need a later comparison to show whether any change held.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

## Safety profile

Injectable MOTS-c safety is mainly a local-injection, product-quality, immune-response, and metabolic-context question. Long-term mitochondrial-signaling exposure and durable metabolic effects remain unresolved.[\[42\]](<https://api.fda.gov/drug/drugsfda.json?search=%22MOTS-c%22&limit=1>) [\[44\]](<https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026>) [\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

### Common side effects

- Injection-site pain or swelling [\[45\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### Cautions

- Unapproved injectable quality[\[45\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- Metabolic disease context[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

### What we don't know

Chronic human safety, immunogenicity, and durable metabolic effects are not established.[\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>) [\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

## Who MOTS-c is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Avoid because reproductive and developmental safety have not been established.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)
- **Active cancer or complex metabolic disease**

  Specialist review is warranted because mitochondrial and metabolic signaling can be disease-context dependent.[\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Glucose-lowering medications**

  Glucose-lowering medications can make glucose and insulin-sensitivity changes harder to interpret during injectable MOTS-c use; this is a theoretical metabolic caution.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

## Pairing notes

### Commonly included in these stacks

[**NAD+ / MOTS-c / 5-Amino-1MQ** NAD+ / MOTS-c / 5-Amino-1MQ is a mitochondrial and metabolic stack concept built around cellular energy handling. Direct NAD+ provides the redox cofactor itself, MOTS-c targets mitochondrial stress-response signaling, and 5-Amino-1MQ targets NNMT-linked nicotinamide metabolism. NAD+ MOTS-c 5-Amino-1MQ](<https://pepflow.app/stacks/nad-mots-c-5-amino-1mq/>)

## Regulatory status

### United States

MOTS-c has no FDA-approved injectable human use as of 2026-06-21. Its separate 503A question is pending FDA PCAC discussion on July 23, 2026; that process does not establish approval, safety, or effectiveness.[\[42\]](<https://api.fda.gov/drug/drugsfda.json?search=%22MOTS-c%22&limit=1>) [\[44\]](<https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Approved · As of 2026-06-21, MOTS-c was not FDA-approved as an injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval.[\[42\]](<https://api.fda.gov/drug/drugsfda.json?search=%22MOTS-c%22&limit=1>) [\[44\]](<https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026>) [\[45\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) | Under Review · MOTS-c-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance.[\[42\]](<https://api.fda.gov/drug/drugsfda.json?search=%22MOTS-c%22&limit=1>) [\[44\]](<https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026>) [\[45\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |

### Injectable

FDA drug approval

Not Approved

As of 2026-06-21, MOTS-c was not FDA-approved as an injectable drug. The July 23, 2026 PCAC agenda concerns possible 503A bulk-substance inclusion, not FDA drug approval.[\[42\]](<https://api.fda.gov/drug/drugsfda.json?search=%22MOTS-c%22&limit=1>) [\[44\]](<https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026>) [\[45\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

503A compounding

Under Review

MOTS-c-related bulk substances are scheduled for FDA PCAC discussion on July 23, 2026 for possible 503A Bulks List inclusion. That review is not FDA approval or a safety clearance.[\[42\]](<https://api.fda.gov/drug/drugsfda.json?search=%22MOTS-c%22&limit=1>) [\[44\]](<https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026>) [\[45\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### International

EU/Europe, UK, Canada, and Australia should be checked by local product and claim; no approved therapeutic MOTS-c product was found in the reviewed official sources.

### Sports & competition

WADA's 2026 Prohibited List does not specifically name MOTS-c, but tested athletes should treat systemic use of a non-approved pharmacological substance as an S0 risk unless cleared through anti-doping review.[\[47\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## How it works

MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA. Its core mechanism is mitonuclear signaling: under metabolic stress, MOTS-c can move into the nucleus and influence gene programs tied to AMPK activity, glucose handling, and cellular stress adaptation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29983246/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/31378979/>)

That biology makes injectable MOTS-c plausible for metabolic and exercise-adaptation research, but the mechanism is not the same as proven insulin-sensitivity, endurance, or longevity benefit. Human trials still need to show whether systemic exposure produces meaningful outcomes rather than only stress-response signals.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>) [\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

## Research gaps & open questions

What the current literature has not yet settled about MOTS-c:

01

The ongoing Phase 2 program needs to publish results showing whether MOTS-c improves insulin sensitivity in people and how large the effect is.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

02

Human studies need to establish the dose, how the body absorbs and clears MOTS-c, and which safety checks are needed; research-market protocols cannot answer these questions.[\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

03

Controlled trials need to show whether MOTS-c actually improves endurance, strength, or recovery in people rather than relying on exercise-related mechanisms.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/33554779/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

## Common questions

### What is MOTS-c best known for?

MOTS-c is best known as a mitochondrial-derived peptide studied for metabolic stress signaling, insulin-sensitivity biology, and exercise-adaptation pathways.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

### Is MOTS-c proven for weight loss?

No. Injectable MOTS-c has metabolic rationale and active human trial activity, but posted controlled human weight-loss outcomes are not established.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

### Is MOTS-c FDA-approved?

No. MOTS-c has no FDA-approved injectable human use, and the July 23, 2026 PCAC discussion is a 503A compounding review, not approval.[\[42\]](<https://api.fda.gov/drug/drugsfda.json?search=%22MOTS-c%22&limit=1>) [\[44\]](<https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026>)

## Myths & misconceptions

### Myth

MOTS-c is a proven exercise mimetic in humans.

### Reality

The exercise-mimetic idea comes from mechanism and preclinical biology; human performance outcomes remain unproven.[\[16\]](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)

### Myth

A recruiting MOTS-c trial proves it works.

### Reality

A recruiting trial shows research activity, not benefit. Results need to be posted or published before raising confidence.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

## History & discovery

MOTS-c was introduced as a mitochondrial-derived peptide encoded by the 12S rRNA region, turning mitochondrial DNA from a genome of energy machinery into a source of signaling peptides.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/31378979/>)

The original Cell Metabolism paper linked MOTS-c to metabolic homeostasis, obesity resistance, and insulin sensitivity in cell and mouse models.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/25738459/>)

Follow-up work showed MOTS-c can move to the nucleus during metabolic stress and regulate nuclear gene expression, broadening interest beyond simple mitochondrial biology.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/29983246/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/31378979/>)

A Phase 2 trial is recruiting adults with prediabetes and overweight or obesity, marking active clinical translation without posted efficacy outcomes.[\[46\]](<https://clinicaltrials.gov/study/NCT07505745>)

## Published research 47 citations

- [\[1\] **The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.** Cell metabolism, 2015 Mar 3. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/25738459/>)
- [\[2\] **MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism.** Free radical biology & medicine, 2016 Nov. review.](<https://pubmed.ncbi.nlm.nih.gov/27216708/>)
- [\[3\] **Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals.** Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2018 Aug. review.](<https://pubmed.ncbi.nlm.nih.gov/29593067/>)
- [\[4\] **Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance.** Pediatric diabetes, 2018 Apr 25. review.](<https://pubmed.ncbi.nlm.nih.gov/29691953/>)
- [\[5\] **The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.** Cell metabolism, 2018 Sep 4. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/29983246/>)
- [\[6\] **MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus.** BioEssays : news and reviews in molecular, cellular and developmental biology, 2019 Sep. review.](<https://pubmed.ncbi.nlm.nih.gov/31378979/>)
- [\[7\] **β-Amyloid and mitochondrial-derived peptide-c are additive predictors of adverse outcome to high-on-treatment platelet reactivity in type 2 diabetics with revascularized coronary artery disease.** Journal of thrombosis and thrombolysis, 2020 Apr. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/32052315/>)
- [\[8\] **A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c.** Aging, 2021 Jan 19. review.](<https://pubmed.ncbi.nlm.nih.gov/33468709/>)
- [\[9\] **MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.** Nature communications, 2021 Jan 20. review.](<https://pubmed.ncbi.nlm.nih.gov/33473109/>)
- [\[10\] **MOTS-c reduces myostatin and muscle atrophy signaling.** American journal of physiology. Endocrinology and metabolism, 2021 Apr 1. review.](<https://pubmed.ncbi.nlm.nih.gov/33554779/>)
- [\[11\] **MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway.** Biochimica et biophysica acta. Molecular basis of disease, 2021 Jun 1. animal.](<https://pubmed.ncbi.nlm.nih.gov/33722744/>)
- [\[12\] **Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans.** Journal of applied physiology (Bethesda, Md. : 1985), 2021 Sep 1. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34351816/>)
- [\[13\] **Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.** Scientific reports, 2021 Aug 19. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/34413391/>)
- [\[14\] **The mitochondrial signaling peptide MOTS-c improves myocardial performance during exercise training in rats.** Scientific reports, 2021 Oct 11. animal.](<https://pubmed.ncbi.nlm.nih.gov/34635713/>)
- [\[15\] **\[Effects of exercise intervention on mitochondrial-derived peptide MOTS-c in the germ cells of obese men\].** Zhonghua nan ke xue = National journal of andrology, 2021 Jun. review.](<https://pubmed.ncbi.nlm.nih.gov/34914298/>)
- [\[16\] **Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c).** Diabetes & metabolism journal, 2022 May. review.](<https://pubmed.ncbi.nlm.nih.gov/35656563/>)
- [\[17\] **Mitochondrial derived peptide MOTS-c prevents the development of heart failure under pressure overload conditions in mice.** Journal of cellular and molecular medicine, 2022 Nov. animal.](<https://pubmed.ncbi.nlm.nih.gov/36156853/>)
- [\[18\] **MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases.** International journal of molecular sciences, 2022 Oct 9. review.](<https://pubmed.ncbi.nlm.nih.gov/36233287/>)
- [\[19\] **Circulating levels of MOTS-c in patients with breast cancer treated with metformin.** Aging, 2022 Dec 6. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/36490309/>)
- [\[20\] **Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging.** Journal of translational medicine, 2023 Jan 20. review.](<https://pubmed.ncbi.nlm.nih.gov/36670507/>)
- [\[21\] **MOTS-c Functionally Prevents Metabolic Disorders.** Metabolites, 2023 Jan 13. review.](<https://pubmed.ncbi.nlm.nih.gov/36677050/>)
- [\[22\] **MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation.** Frontiers in endocrinology, 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/36761202/>)
- [\[23\] **Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases.** Diabetes & metabolism journal, 2023 May. review.](<https://pubmed.ncbi.nlm.nih.gov/36824008/>)
- [\[24\] **Role of MOTS-c in the regulation of bone metabolism.** Frontiers in physiology, 2023. review.](<https://pubmed.ncbi.nlm.nih.gov/37200834/>)
- [\[25\] **MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria.** Mitochondrion, 2023 Jul. review.](<https://pubmed.ncbi.nlm.nih.gov/37307934/>)
- [\[26\] **Impact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer.** Current radiopharmaceuticals, 2024. review.](<https://pubmed.ncbi.nlm.nih.gov/38314601/>)
- [\[27\] **The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study.** Blood purification, 2024. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/39111290/>)
- [\[28\] **MOTS-c Impact on Muscle Cell Differentiation and Metabolism Across Fiber Types.** Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2025 Jan 21. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/39876762/>)
- [\[29\] **MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study.** Medicina (Kaunas, Lithuania), 2025 Feb 12. review.](<https://pubmed.ncbi.nlm.nih.gov/40005438/>)
- [\[30\] **Circulating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement.** Biologics : targets & therapy, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40104672/>)
- [\[31\] **MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes.** Redox biology, 2025 Jul. review.](<https://pubmed.ncbi.nlm.nih.gov/40403491/>)
- [\[32\] **MOTS-c-modified functional self-assembly peptide hydrogels enhance the activity of nucleus pulposus-derived mesenchymal stem cells of intervertebral disc degeneration.** Materials today. Bio, 2025 Jun. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/40510834/>)
- [\[33\] **Mitochondria-derived peptide MOTS-c and its role in OSA pathogenesis: a potential therapeutic target?** Sleep and biological rhythms, 2025 Jul. review.](<https://pubmed.ncbi.nlm.nih.gov/40538382/>)
- [\[34\] **Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart.** Frontiers in physiology, 2025. review.](<https://pubmed.ncbi.nlm.nih.gov/40661667/>)
- [\[35\] **Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.** Medicine and science in sports and exercise, 2025 Dec 1. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40674654/>)
- [\[36\] **A mitochondrial-derived peptide MOTS-c contributes to the protective effect against brain injury associated with LPS-induced sepsis by strengthening the blood-brain barrier's ultrastructure.** The International journal of neuroscience, 2026 Mar. review.](<https://pubmed.ncbi.nlm.nih.gov/40753494/>)
- [\[37\] **Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes.** Experimental & molecular medicine, 2025 Aug. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/40855115/>)
- [\[38\] **MOTS-C levels ın ındividuals with and without obesity and ıts association with ınflammation, insulin resistance and endothelial dysfunction.** Archives of endocrinology and metabolism, 2025 Sep 26. review.](<https://pubmed.ncbi.nlm.nih.gov/41004666/>)
- [\[39\] **MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism.** Free radical biology & medicine, 2025 Dec 16. review.](<https://pubmed.ncbi.nlm.nih.gov/41043625/>)
- [\[40\] **MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications and potential treatment.** Life sciences, 2025 Dec 1. review.](<https://pubmed.ncbi.nlm.nih.gov/41083123/>)
- [\[41\] **MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner.** Free radical biology & medicine, 2026 Mar 16. review.](<https://pubmed.ncbi.nlm.nih.gov/41520850/>)
- [\[42\] **Drugs@FDA/openFDA query for MOTS-c** U.S. Food and Drug Administration / openFDA. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22MOTS-c%22&limit=1>)
- [\[43\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[44\] **July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee** U.S. Food and Drug Administration, 2026-04-16. regulatory.](<https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026>)
- [\[45\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[46\] **MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity** ClinicalTrials.gov. clinical trial registry.](<https://clinicaltrials.gov/study/NCT07505745>)
- [\[47\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency, 2026. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Mitochondrial peptide

**Tier**

D

**Evidence**

45% Preliminary

**Safety**

Limited Data

**FDA status**

Not Approved

**Injectable 503A**

Under Review

**Citations**

[47 citations](<https://pepflow.app/peptides/mots-c/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Insulin sensitivity and metabolic health
- Mitochondrial stress adaptation
- Exercise adaptation and muscle metabolism
- Cardiovascular risk reduction
- Longevity and age-related decline

### Common side effects

- Injection-site pain or swelling

### Also known as

- MOTS-c
- Mitochondrial ORF of the 12S rRNA type-c
- MOTS-c peptide

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Mots C Dosage Calculator](<https://pepflow.app/blog/mots-c-dosage-calculator/>)
- [MOTS-c dosage guide](<https://pepflow.app/peptides/mots-c/dosage/>)
- [NAD+ / MOTS-c / 5-Amino-1MQ](<https://pepflow.app/stacks/nad-mots-c-5-amino-1mq/>)
